Details for New Drug Application (NDA): 217131
✉ Email this page to a colleague
NDA 217131 describes ASCORBIC ACID, which is a drug marketed by Fresenius Kabi Usa and Stira and is included in two NDAs. It is available from two suppliers. Additional details are available on the ASCORBIC ACID profile page.
The generic ingredient in ASCORBIC ACID is ascorbic acid. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the ascorbic acid profile page.
The generic ingredient in ASCORBIC ACID is ascorbic acid. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the ascorbic acid profile page.
Summary for 217131
| Tradename: | ASCORBIC ACID |
| Applicant: | Fresenius Kabi Usa |
| Ingredient: | ascorbic acid |
| Patents: | 0 |
Suppliers and Packaging for NDA: 217131
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ASCORBIC ACID | ascorbic acid | SOLUTION;INTRAVENOUS | 217131 | ANDA | Fresenius Kabi USA, LLC | 65219-027 | 65219-027-50 | 25 VIAL, GLASS in 1 TRAY (65219-027-50) / 50 mL in 1 VIAL, GLASS (65219-027-05) |
| ASCORBIC ACID | ascorbic acid | SOLUTION;INTRAVENOUS | 217131 | ANDA | Fresenius Kabi USA, LLC | 65219-027 | 65219-027-55 | 1 VIAL, GLASS in 1 CARTON (65219-027-55) / 50 mL in 1 VIAL, GLASS |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 25,000MG/50ML (500MG/ML) | ||||
| Approval Date: | Aug 7, 2025 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
